Search clinical trials for: SPM 962

Total 1392 results

Otsuka Pharmaceutical Co., Ltd.

Completed

Study of SPM 962 in Patients With Restless Legs Syndrome (RLS)

Idiopathic Restless Legs Syndrome

Japan
UCB Pharma

Completed

A Trial to Compare the Efficacy of Rotigotine Transdermal Patch to That of Ropinirole on Early Morning Motor Impairment and Sleep Disorders in Subjects With Early-Stage, Idiopathic Parkinson's Disease

Parkinson's Disease

Germany
UCB Pharma

Completed

Rotigotine Patch in Subjects With Advanced Stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled on Levodopa

Parkinson Disease, Idiopathic

Germany
Otsuka Pharmaceutical Co., Ltd.

Completed

A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients

Early Parkinson's Disease

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-Term Extension Trial From Late Phase II of SPM 962 in Advanced Parkinson's Disease Patients

Parkinson's Disease

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Dose-finding Study for SPM 962 in Advanced Parkinson's Disease Patients

Parkinson's Disease

Japan
Sparrow Pharmaceuticals

Recruiting

SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor (ACSPIRE)

Autonomous Cortisol Secretion (ACS) | ACTH-Independent Cushing Syndrome | ACTH-Independent Adrenal Cushing Syndrome, Somatic

United States, United Kingdom, France, Romania
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-Term Extension Trial From Late Phase II of SPM 962 in Patients With Restless Legs Syndrome (RLS)

Idiopathic Restless Legs Syndrome
Otsuka Pharmaceutical Co., Ltd.

Completed

A Dose-ranging Study for SPM 962 in Parkinson's Disease Patients

Parkinson's Disease

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Placebo-Controlled Study for SPM 962 in Restless Legs Syndrome (RLS) Patients

Idiopathic Restless Legs Syndrome

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients

Parkinson's Disease

Japan
University of California, San Francisco

Completed

THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD: Specialized Pro-Resolving Mediators in Patients With Peripheral Artery Disease

Vascular Diseases | Osteoarthritis | Peripheral Arterial Disease | Claudication | Vascular Calcification | Claudication, Intermittent | Vascular Occlusion

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease Patients

Parkinson's Disease

Japan
Proaparts srl

Unknown

Efficacy, Safety and Pharmacokinetics of SPK-843 in the Treatment of Pulmonary Mycosis

Cryptococcosis or Aspergillosis Infections

Italy
Otsuka Pharmaceutical Co., Ltd.

Completed

A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients

Parkinson's Disease

Japan
Bayer

Completed

To Evaluate Eye Installation-Tear Free

Sunscreening Agents

United States
University of California, Los Angeles

Completed

Clinical Evaluation of Morcher Artificial Iris Diaphragms

Aniridia | Iris; Deformity

United States
UCB Pharma

Completed

An Open-Label Follow-on Trial to Assess the Long-Term Safety and Efficacy of Oral SPM 927 in Subjects With Postherpetic Neuralgia (PHN)

Postherpetic Neuralgia

Germany
UCB Pharma

Completed

A Trial to Assess the Efficacy and Safety of SPM 927 in Subjects With Painful Distal Diabetic Neuropathy

Diabetic Neuropathy

United States
UCB Pharma

Completed

A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg/Day and 400mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization

Partial Seizures With or Without Secondary Generalization

Germany
UCB Pharma

Completed

SPM 927 (400mg/Day and 600mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization

Epilepsy
University of North Carolina, Chapel Hill
Metagenics, Inc.; North Carolina Translational and Clinical Sciences Institute

Completed

Bioavailability of SPMs in Obese Humans

Obesity Adult Onset

United States
UCB Pharma

Completed

Trial to Assess the Efficacy and Safety of SPM 927 (200, 400, and 600mg/Day) in Subjects With Painful Distal Diabetic Neuropathy

Diabetic Neuropathies

United States
UCB Pharma

Completed

Safety and Tolerability of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizures

Epilepsies, Partial

United States
Medtronic - MITG

Terminated

Clinical Management With SPM System and Validation of the SPM 5 Hour Cutoff in Patients With Symptoms of Gastroparesis

Gastroparesis

United States
UCB Pharma
SCHWARZ BIOSCIENCES GmbH - Part of UCB Group

Completed

A Trial to Assess the Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Diabetic Neuropathy

Painful Diabetic Neuropathy

Germany
Sparrow Pharmaceuticals

Active, not recruiting

SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome (RESCUE)

Cortisol; Hypersecretion | Cortisol Overproduction | Cushing's Syndrome I | Cushing Disease Due to Increased ACTH Secretion | Cortisol Excess | Ectopic ACTH Secretion

United States, Bulgaria, Romania
UCB Pharma

Completed

Rotigotine Restless Legs Syndrome Dose Finding Trial

Idiopathic Restless Leg Syndrome

Germany
UCB Pharma

Completed

Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of Parkinson Symptoms

Parkinson's Disease
Pfizer

Completed

Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase

Overactive Bladder

United States
Pfizer

Completed

Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome

Overactive Bladder Syndrome

Germany
Pfizer

Completed

A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome

Overactive Bladder Syndrome

Germany
Pfizer

Completed

Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome

Overactive Bladder Syndrome

United States
Pfizer

Completed

Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome

Overactive Bladder
Queen Mary University of London
Metagenics, Inc.

Unknown

SPM Regulation by Fish Oil Supplements in Healthy Volunteers

Healthy Volunteers

United Kingdom
UCB Pharma

Completed

A Trial to Assess the Efficacy and Safety of SPM 927 (Lacosamide) in Subjects With Painful Distal Diabetic Neuropathy

Diabetic Neuropathy

Germany
Le Syndicat Intercommunal pour le Thermalisme et...
University Grenoble Alps; Floralis

Recruiting

Assessment of the Effect of Spa Therapy on the Quality of Life of Patients With Chronic Venous Insufficiency (NEYRAC) (NEYRAC)

Chronic Venous Insufficiency

France
National University of Natural Medicine
Metagenics, Inc.

Completed

Influence of an Omega-3 SPM Supplement on Quality of Life

Chronic Pain

United States
Michigan State University
Massachusetts General Hospital; University of Michigan; Saint Joseph Mercy Health... and other collaborators

Completed

Michigan Stroke Transitions Trial (MISTT)

Acute Stroke

United States
Mayo Clinic

Completed

Silver-impregnated Suprapubic Catheters (SPC) in Urogynecology

Urinary Tract Infection | Infection Associated With Catheter

United States
David Sheyn
Northwestern University; University of Louisville

Not yet recruiting

Cyclic Versus Continuous Sacral Neuromodulation for LUTS

Overactive Bladder Syndrome
Shenzhen People's Hospital

Withdrawn

Arthroscopic Partial Meniscectomy Time Window

Meniscus Lesion

China
Cancer Intelligence Care Systems, Inc.
Stella Pharma Corporation

Completed

Boron Neutron Capture Therapy Using CICS-1 and SPM-011 for Malignant Melanoma and Angiosarcoma

Angiosarcoma | Malignant Melanoma

Japan
Supernus Pharmaceuticals, Inc.

Completed

Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD

Attention-Deficit/Hyperactivity Disorder (ADHD)

United States
University of Delaware
University of Pennsylvania; Christiana Care Health Services; Indiana University

Completed

Promoting Recovery Optimization With WALKing Exercise After Stroke (PROWALKS)

Stroke

United States
Association Francaise pour la Recherche Thermale
University Hospital, Grenoble; Floralis

Withdrawn

SPA Therapy in the Treatment of Sleep Apnea Syndrome (THERMA-SAS)

Obstructive Sleep Apnea Syndrome | Chronic Venous Insufficiency

France
University of California, Los Angeles
National Institute of Nursing Research (NINR); Duke University; East Carolina... and other collaborators

Recruiting

Skin Change Actions by Nursing (SCAN)

Pressure Injury

United States
AbbVie

Recruiting

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)

Healthy Volunteers | Generalized Anxiety Disorder (GAD) | Bipolar Disorder (BPD)

United States
NeurAxon Inc.

Completed

Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia

Post Herpetic Neuralgia

United States, Canada
Analog Device, Inc.

Recruiting

Feasibility and Efficacy Study of the CardioPulmonary Monitoring (CPM) System in Patients With Chronic Heart Failure

Heart Failure

United States

3

Subscribe